Company Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Kiniksa Pharmaceuticals, Ltd.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
17.88 ^USD	+1.53%		+5.74%	+1.94%

Apr. 23	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	MT
Apr. 23	Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1Î±), and interleukin-1beta (IL-1Î²), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRÎ±).

Number of employees: 297

USD in Million	2022	Weight	2023	Weight	Delta
Therapeutic Medicines 100.0 %	220	100.0 %	270	100.0 %	+22.74%

USD in Million	2022	Weight	2023	Weight	Delta
Bermuda 100.0 %	220	100.0 %	270	100.0 %	+22.74%

Managers	Title	Age	Since
Eben Tessari FOU	Founder	42	15-06-30
Sanj Patel CEO	Chief Executive Officer	54	15-06-30
Mark Ragosa DFI	Director of Finance/CFO	50	18-04-30
Chad Morin CMP	Compliance Officer	-	20-09-30
John Paolini CTO	Chief Tech/Sci/R&D Officer	59	16-07-31
Rachel Frank IRC	Investor Relations Contact	-	-
Madelyn Zeylikman LAW	General Counsel	-	20-07-31
Ross Moat PRN	Corporate Officer/Principal	43	18-12-31
Martina Struck LAW	General Counsel	-	17-12-31
Melissa Manno HRO	Human Resources Officer	-	16-12-31

Members of the board	Title	Age	Since
Felix Baker BRD	Director/Board Member	55	15-09-30
Barry D. Quart BRD	Director/Board Member	67	15-09-30
Thomas Malley BRD	Director/Board Member	55	16-11-30
Richard Levy BRD	Director/Board Member	66	19-03-03
Kim Popovits BRD	Director/Board Member	65	18-01-31
G. Cole BRD	Director/Board Member	68	20-07-26
Stephen Biggar BRD	Director/Board Member	53	15-09-30
Sanj Patel CEO	Chief Executive Officer	54	15-06-30
Tracey McCain BRD	Director/Board Member	56	18-01-31

	Vote	Quantity	Free-Float	Total Float
Stock A	1	16,057,618	0	54.58 %
Stock B	1	12,781,964	0
Stock C	1	1,795,158	0
Stock D	1	40,305,405	38,720,038 ( 96.07 %)

Name	Equities	%	Valuation
BlackRock Advisors LLC 7.600 %	3,038,415	7.600 %	60 M $
Vanguard Fiduciary Trust Co. 7.417 %	2,965,299	7.417 %	59 M $
The Vanguard Group, Inc. 7.417 %	2,965,299	7.417 %	59 M $
Rubric Capital Management LP 7.272 %	2,907,501	7.272 %	57 M $
Rubric Capital Management LP 7.272 %	2,907,501	7.272 %	57 M $
Fairmount Funds Management LLC 7.212 %	2,883,221	7.212 %	57 M $
Fairmount Funds Management LLC 7.212 %	2,883,221	7.212 %	57 M $
Baker Bros. Advisors LP 7.027 %	2,809,577	7.027 %	55 M $
Morgan Stanley Investment Management, Inc. 3.991 %	1,595,479	3.991 %	31 M $
Pictet Asset Management Holding SA 3.929 %	1,570,816	3.929 %	31 M $

Name	Equities	%	Valuation
Baker Bros. Advisors LP 100.00 %	16,057,618	100.00 %	317 M $

Name	Equities	%	Valuation
Sanj Patel 37.18 %	1,526,160	37.18 %	30 M $
Robert Desnick 5.215 %	214,101	5.215 %	4 M $

Name	Equities	%	Valuation
Baker Bros. Advisors LP 70.91 %	12,781,964	70.91 %	252 M $
HHLR Advisors Ltd. 18.99 %	3,423,385	18.99 %	68 M $

Kiniksa Pharmaceuticals Ltd.

100 Hayden Avenue

02421, Lexington

http://www.kiniksa.com

address Kiniksa Pharmaceuticals, Ltd.(KNSA)

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.88 USD

Average target price

29.2 USD

Spread / Average Target

+63.31%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
KINIKSA PHARMACEUTICALS, LTD.	+1.94%	1.27B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.05%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.31%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs